Fzd7 inhibitors, monoclonal antibodies against ROR2, and small-molecule inhibitors of EV biogenesis or uptake are under active investigation in several cancers [91,92,93,94,95] and may offer combinatory strategies with androgen deprivation and/or chemotherapy to mitigate EV-mediated pro-metastatic signalling. The gene discussed is ROR2; the disease is cancer.